Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Stoke Therapeutics granted inducement stock options for roughly 245,920 total shares to newly-appointed CIO Stephen Aschettino and seventeen other new employees, effective October 15, 2026. All options carry a $24.61 exercise price (equal to the October 15 close), a 4-year vesting schedule with a 1-year cliff, and a 10-year term under the 2023 Inducement Plan.
Key figures
- Option term
- 10 years
- Exercise price
- 24.61
- Vesting period
- 4 years
- Cio option shares
- 70000
- Other employee option shares
- 175920
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.